HELUS Pharma: Transitioning From Psychedelic Research To Late-Stage Clinical Neuroscience
2026-02-24 23:55:05 ET
Thesis: New Ticker to Signal Change
As you know, when I last converged HELUS Pharma ( HELP ), we referred to it as Cybin. Since then, the company has formally transitioned at the start of January this year, when it transferred its exchange listing from the NYSE American to the Nasdaq Global Market. They then began trading under the new ticker on January 5th. As for the reason behind the management explained that the rebrand and exchange move were, for the most part, intended to better reflect the company's evolution. We're seeing Helus still stuck in a research-stage psychedelic drug developer stage but trying to push into a clinical-stage pharma company, with preparations ramping up for potential commercialisation of its lead serotonin-modulating therapies. Besides the ticker changing, their lead candidates also swapped names to align with the new company name....
Read the full article on Seeking Alpha
For further details see:
HELUS Pharma: Transitioning From Psychedelic Research To Late-Stage Clinical Neuroscience
NASDAQ: HELP
HELP Trading
-0.67% G/L:
$7.45 Last:
177,117 Volume:
$7.65 Open:
